false
Catalog
The Utilization of Medication for Opioid Use Disor ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
This document appears to be a presentation or transcript of a webinar on the utilization of medication for opioid use disorder in an outpatient setting. The webinar was part of an initiative by the American Psychiatric Association (APA) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The document includes information on the Clinical Support System for Serious Mental Illness (CSS-SMI), continuing education credits, faculty members, and disclosures.<br /><br />The content of the document covers a range of topics related to opioid use disorder and its treatment. It highlights the increasing rates of opioid overdose deaths, the statistics on illicit drug use and the sources of pain relievers, and the co-occurring diagnoses often seen with opioid use disorder, such as anxiety-related disorders, depression-related disorders, ADHD, PTSD, and schizophrenia. The document also discusses the risk factors for opioid use disorder, the screening tools and techniques used, and the various medications for opioid use disorder, including methadone, buprenorphine, and naltrexone.<br /><br />The document provides information on the ASAM criteria for determining the level of care for patients with addiction and co-occurring disorders, as well as the importance of naloxone administration in cases of opioid overdose. It emphasizes the need to address the stigma surrounding opioid use disorder and the importance of using appropriate language when discussing the condition.<br /><br />The document concludes with information on how to claim continuing education credits for the webinar and announces an upcoming webinar on dialectical behavior therapy for serious and persistent mental illness.<br /><br />Please note that the summary provided is based on the content headings and does not include the specific details or discussions within each section.
Keywords
medication
opioid use disorder
outpatient setting
Clinical Support System for Serious Mental Illness
co-occurring diagnoses
screening tools
methadone
buprenorphine
naltrexone
naloxone administration
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English